Scientists develop therapeutic protein, protect nerve cells from Huntington's Disease

September 13, 2016, Case Western Reserve University
A montage of three images of single striatal neurons transfected with a disease-associated version of huntingtin, the protein that causes Huntington's disease. Nuclei of untransfected neurons are seen in the background (blue). The neuron in the center (yellow) contains an abnormal intracellular accumulation of huntingtin called an inclusion body (orange). Credit: Wikipedia/ Creative Commons Attribution 3.0 Unported license

A new scientific study reveals one way to stop proteins from triggering an energy failure inside nerve cells during Huntington's disease. Huntington's disease is an inherited genetic disorder caused by mutations in the gene that encodes huntingtin protein. Approximately 30,000 Americans have mutant huntingtin protein which can impair energy-producing parts of nerve cells called mitochondria. The mutant protein destroys nerve cells and slowly chips away at a person's ability to walk, speak, and control their behavior. Xin Qi, PhD, assistant professor of physiology and biophysics at Case Western Reserve University School of Medicine has been looking for proteins that interact with mutant huntingtin to better understand the initial steps of Huntington's disease progression.

"Because mitochondrial dysfunction has been proposed to play an important role in the pathogenesis of Huntington's disease," said Qi, "we investigated the binding proteins of mutant huntingtin on ." His recent study published in Nature Communications characterized one , valosin-containing protein (VCP) that Qi's research team found in high abundance inside nerve cell mitochondria. Qi and colleagues discovered that VCP is recruited to nerve cell mitochondria by mutant huntingtin protein.

The researchers showed that mice with mutant huntingtin had mitochondria full of VCP, as did nerve cells donated by people with Huntington's disease. The VCP inside mitochondria only interacted with mutant, but not healthy huntingtin protein. According to Qi, "In Huntington's disease, the VCP-mutant huntingtin binding is greatly increased. This abnormal binding causes more VCP accumulation on the mitochondria," Nerve cells with VCP-mutant huntingtin interacting inside them became dysfunctional and self-destructed.

"We found that VCP is a key player in mitochondria-associated autophagy, a mitochondria self-eating process. Over-accumulation of VCP on mitochondria thus results in a great loss of mitochondria, which leads to neuronal cell death due to lack of energy supply." explained Qi. The researchers worked to identify ways to prevent VCP from heading to nerve cell mitochondria and interacting with mutant huntingtin protein once inside.

The team identified the regions of VCP and mutant huntingtin that were interacting. They cleverly designed a small protein, or peptide, with the same regions to disrupt the VCP-mutant interaction. In nerve cells exposed to their peptide, VCP and mutant huntingtin bound the peptide instead of each other. Nerve cells exposed to the novel peptide had healthier mitochondria than unexposed cells. In fact, the peptide prevented VCP from relocating to mitochondria at all, and prevented nerve cell death.

Qi wanted to determine if the peptide had more than subcellular effects, and if it could be used therapeutically to prevent Huntington's disease symptoms. The researchers administered the peptide to mice with Huntington's-like disease and assessed mouse motor skills. Huntington's-like mice exhibit spontaneous movement including excessive clasping, poor coordination, and decreased lifespan. Mice treated with the novel peptide did not experience these symptoms and appeared healthy. Qi concluded that the peptide reduced nerve cell impairment caused by Huntington's disease in the animal model.

The study successfully countered harmful effects of huntingtin and protected in several models of Huntington's disease. According to Qi, the interfering peptide developed in the study "suggests a potential therapeutic option for treatment of Huntington's disease, a with no treatment available." The next step for the researchers will be to optimize the potentially therapeutic peptide for use in human studies.

Explore further: Activity of Huntington's disease gene curbed for six months in mice

More information: Xing Guo et al, VCP recruitment to mitochondria causes mitophagy impairment and neurodegeneration in models of Huntington's disease, Nature Communications (2016). DOI: 10.1038/ncomms12646

Related Stories

Activity of Huntington's disease gene curbed for six months in mice

September 9, 2016
A single injection of a new treatment has reduced the activity of the gene responsible for Huntington's disease for several months in a trial in mice.

Mutations in VCP gene implicated in a number of neurodegenerative diseases

March 14, 2013
New research, published in Neuron, gives insight into how single mutations in the VCP gene cause a range of neurological conditions including a form of dementia called Inclusion Body Myopathy, Paget's Disease of the Bone ...

Potential therapeutic target for Huntington's disease

August 16, 2016
There is new hope in the fight against Huntington's disease. Scientists at the Gladstone Institutes discovered that changing a specific part of the huntingtin protein prevented the loss of critical brain cells and protected ...

Huntington's disease gene dispensable in adult mice

March 7, 2016
Adult mice don't need the gene that, when mutated in humans, causes the inherited neurodegenerative disorder Huntington's disease.

Team finds method to reduce accumulation of damaging Huntington's disease protein

April 15, 2016
A study appearing April 14 in the journal Neuron suggests there may be a new way to change the damaging course of Huntington disease.

Study shows for first time how Huntington's disease protein could cause death of neurons

May 19, 2014
(Medical Xpress)—Scientists at the University of Pittsburgh School of Medicine have identified for the first time a key molecular mechanism by which the abnormal protein found in Huntington's disease can cause brain cell ...

Recommended for you

Environmental factors may trigger onset of multiple sclerosis

October 16, 2018
A new Tel Aviv University study finds that certain environmental conditions may precipitate structural changes that take place in myelin sheaths in the onset of multiple sclerosis (MS). Myelin sheaths are the "insulating ...

Study points to possible new therapy for hearing loss

October 15, 2018
Researchers have taken an important step toward what may become a new approach to restore hearing loss. In a new study, out today in the European Journal of Neuroscience, scientists have been able to regrow the sensory hair ...

Scientists examine how neuropathic pain responds to Metformin

October 15, 2018
Scientists seeking an effective treatment for one type of chronic pain believe a ubiquitous, generic diabetes medication might solve both the discomfort and the mental deficits that go with the pain.

Sugar, a 'sweet' tool to understand brain injuries

October 15, 2018
Australian researchers have developed ground-breaking new technology which could prove crucial in treating brain injuries and have multiple other applications, including testing the success of cancer therapies.

Abnormal vision in childhood can affect brain functions

October 13, 2018
A research team has discovered that abnormal vision in childhood can affect the development of higher-level brain areas responsible for things such as attention.

Study: Ketogenic diet appears to prevent cognitive decline in mice

October 12, 2018
We've all experienced a "gut feeling"—when we know deep down inside that something is true. That phenomenon and others (like "butterflies in the stomach") aptly describe what scientists have now demonstrated: that the gut ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.